JP2020504733A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504733A5
JP2020504733A5 JP2019533490A JP2019533490A JP2020504733A5 JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5 JP 2019533490 A JP2019533490 A JP 2019533490A JP 2019533490 A JP2019533490 A JP 2019533490A JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5
Authority
JP
Japan
Prior art keywords
amino
methyl
oxy
propan
phosphoryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504733A (ja
JP6938637B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067470 external-priority patent/WO2018119013A1/en
Publication of JP2020504733A publication Critical patent/JP2020504733A/ja
Publication of JP2020504733A5 publication Critical patent/JP2020504733A5/ja
Application granted granted Critical
Publication of JP6938637B2 publication Critical patent/JP6938637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533490A 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ Expired - Fee Related JP6938637B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662437753P 2016-12-22 2016-12-22
US62/437,753 2016-12-22
US201762574493P 2017-10-19 2017-10-19
US62/574,493 2017-10-19
PCT/US2017/067470 WO2018119013A1 (en) 2016-12-22 2017-12-20 Antiviral aliphatic ester prodrugs of tenofovir

Publications (3)

Publication Number Publication Date
JP2020504733A JP2020504733A (ja) 2020-02-13
JP2020504733A5 true JP2020504733A5 (enExample) 2021-01-28
JP6938637B2 JP6938637B2 (ja) 2021-09-22

Family

ID=60972454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533490A Expired - Fee Related JP6938637B2 (ja) 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ

Country Status (13)

Country Link
US (1) US10519159B2 (enExample)
EP (1) EP3559011B1 (enExample)
JP (1) JP6938637B2 (enExample)
KR (1) KR20190100250A (enExample)
CN (1) CN110099912B (enExample)
AU (1) AU2017379850B2 (enExample)
BR (1) BR112019013017A2 (enExample)
CA (1) CA3047573A1 (enExample)
MA (1) MA47094A (enExample)
MX (1) MX388757B (enExample)
RU (1) RU2759902C2 (enExample)
TW (1) TW201829412A (enExample)
WO (1) WO2018119013A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
EP3503895B1 (en) * 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
FI3526323T3 (fi) 2016-10-14 2023-06-06 Prec Biosciences Inc Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
MA47131A (fr) 2016-12-22 2021-05-12 Idenix Pharmaceuticals Llc Composés benzyl-amide phosphodiamide antiviraux
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
JP7076158B2 (ja) * 2017-12-21 2022-05-27 深▲チェン▼市塔吉瑞生物医薬有限公司 新規抗ウイルス性ヌクレオシド系逆転写酵素阻害剤
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
CN108586239B (zh) * 2018-04-11 2020-12-29 深圳市前海博扬研究院有限公司 一种3-羟基丙酸甲酯的制备方法
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN111018916B (zh) * 2019-12-30 2022-04-29 天津天士力圣特制药有限公司 一种替诺福韦苯基烷基酯膦酰胺前体的合成方法
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
ES3054072T3 (en) * 2020-08-07 2026-01-29 Gilead Sciences Inc Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022066882A1 (en) * 2020-09-23 2022-03-31 Oncolinea Pharmaceuticals, Inc. Method for treating cancer with a reverse transcriptase inhibitor
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
HRP20100626T1 (hr) 2003-12-30 2011-03-31 Gilead Sciences Fosfonati, monofosfonamidati, bisfosfonamidati za liječenje virusnih bolesti
JP2008538771A (ja) 2005-04-25 2008-11-06 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック テロメラーゼのプロセッシビティーを向上させるための化合物の使用
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
PT2038290E (pt) 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103403014B (zh) 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN102887901B (zh) 2011-07-01 2015-01-07 四川好医生攀西药业有限责任公司 无环核苷酸类似物及其制备方法和应用
CN110343135A (zh) 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
HRP20220651T1 (hr) 2014-09-15 2022-08-19 The Regents Of The University Of California Nukleotidni analozi
CN106188139B (zh) 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TWI639598B (zh) 2015-08-10 2018-11-01 美商默沙東藥廠 抗病毒β-胺基酸酯磷酸二醯胺化合物
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
CN106167504A (zh) * 2015-11-04 2016-11-30 洛阳聚慧医药科技有限公司 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用
RU2604068C1 (ru) * 2015-12-10 2016-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-аминопурин-6-ил)глицил-(s)-глутаминовая кислота, обладающая противотуберкулёзной активностью
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
EP3503895B1 (en) * 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
MA47131A (fr) 2016-12-22 2021-05-12 Idenix Pharmaceuticals Llc Composés benzyl-amide phosphodiamide antiviraux

Similar Documents

Publication Publication Date Title
RU2019122414A (ru) Антивирусные алифатические сложноэфирные пролекарства тенофовира
JP2017105793A5 (enExample)
JP2016179996A5 (enExample)
JP2021063088A5 (enExample)
RU2019122625A (ru) Противовирусные бензиламин-фосфодиамидные соединения
JP2019500387A5 (enExample)
JP2017533968A5 (enExample)
JP2014508804A5 (enExample)
JP2018035142A5 (enExample)
JP2017518334A5 (enExample)
JP2017523225A5 (enExample)
JP2013518107A5 (enExample)
JP2010501584A5 (enExample)
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
JP2019501130A5 (enExample)
JP2017526677A5 (enExample)
JP2014505107A5 (enExample)
JP2020512337A5 (enExample)
JP2017517565A5 (enExample)
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
TN2013000257A1 (en) Immunosuppressant formulations
JP2020128426A5 (enExample)
RU2016142611A (ru) Пролекарственные средства ингибиторов обратной транскриптазы вич
JP2019531356A5 (enExample)
RU2007106930A (ru) Производные хиназолина